Abstract
POWER 3 analysis: 144-week efficacy and safety results for darunavir/ritonavir (DRV/r) 600/100 mg BID in treatment-experienced HIV patients
Highlights
Open AccessPOWER 3 analysis: 144-week efficacy and safety results for darunavir/ritonavir (DRV/r) 600/100 mg BID in treatment-experienced HIV patients
The POWER 3 144-week efficacy and safety results confirm and extend those observed at 24, 48 and 96 weeks
Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here. http://www.biomedcentral.com/content/pdf/1758-2652-11-S1-info.pdf
Summary
POWER 3 analysis: 144-week efficacy and safety results for darunavir/ritonavir (DRV/r) 600/100 mg BID in treatment-experienced HIV patients. Address: 1Chelsea and Westminster Hospital, London, UK, 2EPIMED c/o Vivantes Auguste-Viktoria-Klinikum, Berlin, Germany, 3Hôpital St-Louis, Division of Clinical Microbiology and Infectious Diseases, Paris, France, 4Instituto de Pesquisa Clinica Evandro Chagas-FIOCRUZ, Rio de Janeiro, Brazil and 5Tibotec BVBA, Mechelen, Belgium. Published: 10 November 2008 Journal of the International AIDS Society 2008, 11(Suppl 1):P24 doi:10.1186/1758-2652-11-S1-P24. Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here. http://www.biomedcentral.com/content/pdf/1758-2652-11-S1-info.pdf
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.